Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · Musculoskeletal

Tendon, ligament and musculoskeletal soft-tissue injury — indication assessment

Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.

Document identifier
CEI-IN-22
Series
Indication assessment
Version
2.3
Published
21 Aug 2024
Last reviewed
21 Aug 2024
Next review
21 Aug 2026
Identifier
10.71829/cei.ind.22
Certainty
Not rated
Cycle
2024 Q3
ICD-11
FB50
Category
Musculoskeletal

§1Assessment

§1.1Definition

Acute or overuse injury of tendon, ligament or muscle, with healing assessed by imaging, function and return-to-activity endpoints.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

  1. Time to return to activity
  2. Pain on loading
  3. Tendon thickness and structure on ultrasound
  4. Re-injury rate

§1.3State of the evidence

Distribution of certainty ratingsShare of assessed outcomes at each certainty level.2compounds
HighModerateLowVery low
Figure 1. Certainty ratings across the 2 compounds the Institute assesses for this indication. A high rating for one compound says nothing about another.

The Institute assesses 2 compounds in this indication, drawing on 0 trial records and 1 evidence synthesis. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
  2. Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.